Publication

Double‐Dummy

Oct 26, 2006 · 1 author · 3 topics

Abstract

Abstract Blinding embodies a rich history spanning several centuries. Double‐blinding usually reduces differential assessment of outcomes (information bias), but can also improve compliance and retention of trial participants while reducing biased supplemental care or treatment (sometimes called co‐intervention). With an active treatment control group, different options to double‐blinding present production obstacles, compliance impediments, and unblinding opportunities. To double‐blind in this situation, double‐dummy blinding nearly always becomes indispensable.

Showing the abstract — retrieve the full paper via the Exa API.

Authors

Kenneth F. Schulz

Topics

Pain Management and Placebo EffectMental Health and PsychiatryPharmaceutical industry and healthcare

About

PublishedOct 26, 2006
Citations0
References15

Powered by the Exa API